{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:19:26Z","timestamp":1769559566335,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","award":["K12 NS049453"],"award-info":[{"award-number":["K12 NS049453"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.eplepsyres.2015.02.003","type":"journal-article","created":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T22:32:09Z","timestamp":1423866729000},"page":"18-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox\u2013Gastaut Syndrome"],"prefix":"10.1016","volume":"112","author":[{"given":"Sudha Kilaru","family":"Kessler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0312-4792","authenticated-orcid":false,"given":"Avital","family":"Cnaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis J.","family":"Dlugos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0005","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2010.04.001","article-title":"Measuring outcomes of treatment with antiepileptic drugs in clinical trials","volume":"18","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0010","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/01.WNL.0000103282.62353.85","article-title":"Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy","volume":"62","author":"Boylan","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0015","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/j.1528-1167.2009.02160.x","article-title":"Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial","volume":"50","author":"Brodie","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0020","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.seizure.2007.01.004","article-title":"Comparative retention rates and long-term tolerability of new antiepileptic drugs","volume":"16","author":"Chung","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0025","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejpn.2014.05.008","article-title":"Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines","volume":"18","author":"Coppola","year":"2014","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0030","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.seizure.2010.09.008","article-title":"Rufinamide in children and adults with Lennox\u2013Gastaut syndrome: first Italian multicenter experience","volume":"19","author":"Coppola","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0035","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2010.03113.x","article-title":"Rufinamide in refractory childhood epileptic encephalopathies other than Lennox\u2013Gastaut syndrome","volume":"18","author":"Coppola","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.seizure.2012.09.015","article-title":"Rufinamide for refractory focal seizures: an open-label, multicenter European study","volume":"22","author":"Coppola","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0045","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1055\/s-0032-1324403","article-title":"Rufinamide in children with refractory epilepsy: pharmacokinetics, efficacy, and safety","volume":"43","author":"Dahlin","year":"2012","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0050","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1212\/WNL.58.8_suppl_5.S9","article-title":"Optimizing health outcomes in active epilepsy","volume":"58","author":"Gilliam","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0055","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.62.1.23","article-title":"Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial","author":"Gilliam","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0060","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","article-title":"Rufinamide for generalized seizures associated with Lennox\u2013Gastaut syndrome","volume":"70","author":"Glauser","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpn.2014.05.001","article-title":"Efficacy and safety of rufinamide in children under four years of age with drug-resistant epilepsies","author":"Grosso","year":"2014","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0070","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0075","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Prposoal for revised classification and terminology of the International League Against Epilepsy","volume":"30","author":"ILAE","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0080","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1528-1157.1998.tb01167.x","article-title":"Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy","volume":"39","author":"ILAE","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.eplepsyres.2010.10.017","article-title":"Rufinamide for refractory epilepsy in a pediatric and young adult population","volume":"93","author":"Joseph","year":"2011","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0090","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.seizure.2012.02.006","article-title":"Rufinamide as an adjuvant treatment in children with Lennox\u2013Gastaut syndrome","volume":"21","author":"Kim","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1684\/epd.2013.0557","article-title":"Short-term efficacy and tolerability of rufinamide adjunctive therapy in children with refractory generalised epilepsy","volume":"15","author":"Kim","year":"2013","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1600-0404.2010.01334.x","article-title":"Adjunctive rufinamide in Lennox\u2013Gastaut syndrome: a long-term, open-label extension study","volume":"122","author":"Kluger","year":"2010","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0105","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.yebeh.2010.01.005","article-title":"First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy","volume":"17","author":"Kluger","year":"2010","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0110","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.yebeh.2008.12.013","article-title":"Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience","volume":"14","author":"Kluger","year":"2009","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0115","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/S1059-1311(03)00047-5","article-title":"Measuring the efficacy of antiepileptic drugs","author":"Mohanraj","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0125","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.yebeh.2011.04.057","article-title":"Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome","volume":"21","author":"Mueller","year":"2011","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0130","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.yebeh.2011.04.057","article-title":"Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome","volume":"21","author":"Mueller","year":"2011","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0135","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.eplepsyres.2013.05.002","article-title":"Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation","volume":"106","author":"Novy","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0140","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.yebeh.2010.11.023","article-title":"Rufinamide for the treatment of epileptic spasms","volume":"20","author":"Olson","year":"2011","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0920-1211(00)00185-6","article-title":"Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy","volume":"43","author":"Palhagen","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.yebeh.2014.09.074","article-title":"Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8years","volume":"41","author":"Rosenfeld","year":"2014","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0155","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0404.2005.00505.x","article-title":"New antiepileptic drugs in practice \u2013 how do they perform in the real world?","volume":"181","author":"Sander","year":"2005","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0160","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/epi.12689","article-title":"Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience","volume":"55","author":"Thome-Souza","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0165","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pediatrneurol.2010.04.003","article-title":"Experience with rufinamide in a pediatric population: a single center's experience","volume":"43","author":"Vendrame","year":"2010","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0170","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/j.1528-1167.2008.01552.x","article-title":"The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models","volume":"49","author":"White","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.02.003_bib0175","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/biostatistics\/kxl040","article-title":"The influence of competing-risks setting on the choice of hypothesis test for treatment effect","volume":"8","author":"Williamson","year":"2007","journal-title":"Biostatistics"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121115000224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121115000224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:32:08Z","timestamp":1760275928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121115000224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":35,"alternative-id":["S0920121115000224"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.02.003","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox\u2013Gastaut Syndrome","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}